RMX Biopharma

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML
CompanyDrug

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML

InnoCare Pharma (HKG: 9969; SHA: 688428) announced today that the first patient has been dosed in the registrational Phase III head‑to‑head clinical trial of the Company's novel BCL2 inhibitor mesutoclax…

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer's Disease Diagnosis and Treatment

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan
CompanyDeals

Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan